Clinical trials: Palmoplantar Pustulosis
- Condition Palmoplantar Pustulosis
- Funder type Industry (pharma, biotech, devices)
- Has posted results yes
Generalized Pustular Psoriasis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Generalized Pustular Psoriasis
The main objectives of this study are to evaluate the efficacy, safety and tolerability of imsidolimab in adults with active GPP.
- Trial name
- GPP (NCT03619902)
- Testing
- Imsidolimab
- Where
- 13 sites in United States, Poland and 2 more
- Volunteers
- 8 people
- Sponsor
- Vanda Pharmaceuticals
Palmoplantar Pustulosis
A Study to Test Long-term Treatment With Spesolimab in People With Palmoplantar Pustulosis (PPP) Who Took Part in Previous Studies With Spesolimab
This study is open to people with palmoplantar pustulosis who took part in previous clinical studies of a medicine called spesolimab.
- Trial name
- NCT04493424
- Testing
- Spesolimab
- Where
- 66 sites in United States, Australia and 12 more
- Volunteers
- 108 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis
A Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis
- Trial name
- NCT03988335
- Testing
- RIST4721
- Where
- 17 sites in Canada, Germany
- Volunteers
- 35 people
- Sponsor
- Aristea Therapeutics, Inc.
Psoriasis
Initial Dosing of BI 655130 in Palmoplantar Pustulosis Patients
The primary objective of this trial is to investigate the safety and efficacy of BI 655130 in patients with PPP following multiple intravenous administrations compared to placebo.
- Trial name
- NCT03135548
- Testing
- Spesolimab (low dose), Spesolimab (high dose)
- Where
- 18 sites in Canada, Denmark and 4 more
- Volunteers
- 59 people
- Sponsor
- Boehringer Ingelheim
Generalized Pustular Psoriasis
An Expanded Access Trial in Japan to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
This Expanded Access trial in Japan is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP). This program provides a medicine called spesolimab to people with a GPP flare-up who have no…
- Trial name
- NCT05200247
- Testing
- spesolimab
- Where
- 9 sites in Japan
- Volunteers
- 11 people
- Sponsor
- Boehringer Ingelheim
Generalized Pustular Psoriasis
An Expanded Access Program in China to Provide Spesolimab to People With a Flare-up in Generalized Pustular Psoriasis Who Have no Other Treatment Options
This Expanded Access Program in China is open to people with a serious skin disease called Generalized Pustular Psoriasis (GPP).
- Trial name
- NCT05239039
- Testing
- spesolimab
- Where
- 12 sites in China
- Volunteers
- 39 people
- Sponsor
- Boehringer Ingelheim
Palmoplantar Pustulosis
A Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in Adults With Palmoplantar Pustulosis
A study to evaluate the efficacy and safety, and pharmacokinetic (PK) profile of multiple doses of imsidolimab (ANB019) in adults with palmoplantar pustulosis (PPP)
- Trial name
- POPLAR (NCT03633396)
- Testing
- Imsidolimab
- Where
- 39 sites in United States, Canada and 2 more
- Volunteers
- 59 people
- Sponsor
- Vanda Pharmaceuticals
Moderate to Severe Psoriasis, Generalized Pustular Psoriasis and Erythrodermic Psoriasis
A Study to Test the Efficacy and Safety of Certolizumab Pegol in Japanese Subjects With Moderate to Severe Chronic Psoriasis
The purpose of this study is to demonstrate the efficacy and safety of Certolizumab Pegol (CZP) in the treatment of moderate to severe chronic plaque Psoriasis (PSO) in Japanese subjects.
- Trial name
- NCT03051217
- Testing
- Certolizumab Pegol
- Where
- 33 sites in Japan
- Volunteers
- 127 people
- Sponsor
- UCB Biopharma S.P.R.L.
Generalized Pustular Psoriasis, Erythrodermic Psoriasis
A Study of Ixekizumab (LY2439821) in Participants in Japan With Generalized Pustular Psoriasis and Erythrodermic Psoriasis
The reason for this study is to see if the study drug ixekizumab is safe and effective in participants with generalized pustular psoriasis and erythrodermic psoriasis.
- Trial name
- NCT03942042
- Testing
- Ixekizumab
- Where
- 7 sites in Japan
- Volunteers
- 12 people
- Sponsor
- Eli Lilly and Company
Palmoplantar Pustulosis
Phase 3, Randomized Study of Apremilast in Japanese Participants With Palmoplantar Pustulosis (PPP)
The primary objective of the study is to evaluate the efficacy of apremilast (AMG 407) twice daily (BID) compared with placebo in participants with Palmoplantar Pustulosis (PPP).
- Trial name
- NCT05174065
- Testing
- Apremilast
- Where
- 40 sites in Japan
- Volunteers
- 176 people
- Sponsor
- Amgen
Generalized Pustular Psoriasis, Erythrodermic Psoriasis
A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
The purpose of this study is to evaluate how effective JNJ-77242113 is in participants with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
- Trial name
- NCT06295692
- Testing
- JNJ-77242113
- Where
- 12 sites in Japan
- Volunteers
- 19 people
- Sponsor
- Janssen Pharmaceutical K.K.
Psoriasis
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
The purpose of this study is to investigate the safety and efficacy of two different dose regimens of risankizumab for Japanese subjects with generalized pustular psoriasis (GPP) or erythrodermic psoriasis (EP).
- Trial name
- NCT03022045
- Testing
- risankizumab
- Where
- 9 sites in Japan
- Volunteers
- 18 people
- Sponsor
- AbbVie
Palmoplantar Pustular Psoriasis
Palmoplantar Pustular Psoriasis Efficacy and Safety With Secukinumab
A one year study assessing the efficacy and safety of secukinumab compared with placebo in adult patients with moderate to severe palmoplantar pustular psoriasis - amended with an optional extension treatment period of up to a…
- Trial name
- NCT02008890
- Testing
- Secukinumab 300mg, Secukinumab 150mg
- Where
- 68 sites in Austria, Belgium and 8 more
- Volunteers
- 237 people
- Sponsor
- Novartis Pharmaceuticals
Palmoplantar Pustulosis
A Phase 2b Study to Evaluate RIST4721 in Palmoplantar Pustulosis (PPP)
A 12-week Randomized, Double-blind, Placebo-controlled, Dose Ranging Phase 2 Study to Evaluate the Efficacy and Safety of RIST4721 in Subjects with Palmoplantar Pustulosis followed by an Open-label Extension Phase.
- Trial name
- NCT05194839
- Testing
- RIST4721
- Where
- 51 sites in United States, Canada and 5 more
- Volunteers
- 79 people
- Sponsor
- Aristea Therapeutics, Inc.
Generalized Pustular Psoriasis
Study to Evaluate the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Subjects With GPP
This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of imsidolimab compared with placebo in adult subjects with generalized pustular psoriasis (GPP).
- Trial name
- GEMINI-1 (NCT05352893)
- Testing
- 750 mg Imsidolimab, 300 mg Imsidolimab
- Where
- 65 sites in United States, Australia and 13 more
- Volunteers
- 45 people
- Sponsor
- Vanda Pharmaceuticals
Palmoplantaris Pustulosis
A Study to Evaluate the Efficacy and Safety of Apremilast (CC-10004) in Japanese Subjects With Palmoplantar Pustulosis
This study will evaluate whether apremilast is better than placebo (inactive substance in the same form as the drug) for the treatment in Japanese subjects with PPP.
- Trial name
- NCT04057937
- Testing
- Apremilast
- Where
- 22 sites in Japan
- Volunteers
- 90 people
- Sponsor
- Amgen
Palmoplantar Pustulosis (PPP)
A Study to Test How Effective and Safe Different Doses of BI 655130 Are in Patients With a Moderate to Severe Form of the Skin Disease Palmoplantar Pustulosis
The primary objective is to provide dose-ranging data for 4 dose regimens of BI 655130 compared to placebo on the primary endpoint of percentage change from baseline in PPP ASI at Week 16.
- Trial name
- NCT04015518
- Testing
- Spesolimab
- Where
- 88 sites in United States, Australia and 13 more
- Volunteers
- 152 people
- Sponsor
- Boehringer Ingelheim
Generalized Pustular Psoriasis
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study.
- Trial name
- NCT04399837
- Testing
- Spesolimab
- Where
- 72 sites in United States, Argentina and 21 more
- Volunteers
- 123 people
- Sponsor
- Boehringer Ingelheim
Generalized Pustular Psoriasis (GPP), Adalimumab
Study to Investigate Efficacy and Safety of Adalimumab in Japanese Subjects With Generalized Pustular Psoriasis (GPP)
The purpose of this study was to investigate the efficacy, safety, and pharmacokinetics of adalimumab in Japanese participants with generalized pustular psoriasis (GPP) who did not have an adequate response to their currently…
- Conditions
- Generalized Pustular Psoriasis (GPP), Adalimumab, Japanese
- Trial name
- NCT02533375
- Testing
- Adalimumab
- Volunteers
- 10 people
- Sponsor
- AbbVie
Generalized Pustular Psoriasis
Effisayil™ 1: A Study to Test Spesolimab (BI 655130) in Patients With a Flare-up of a Skin Disease Called Generalized Pustular Psoriasis
To evaluate efficacy, safety, and tolerability of spesolimab (BI 655130) compared to placebo in patients with Generalized Pustular Psoriasis (GPP) presenting with an acute flare of moderate to severe intensity.
- Trial name
- NCT03782792
- Testing
- Spesolimab
- Where
- 37 sites in United States, China and 10 more
- Volunteers
- 53 people
- Sponsor
- Boehringer Ingelheim